EDTA Chelation Therapy: A Retrospective Study of 2,870 Patients

EDTA Chelation Therapy:
A Retrospective Study of 2,870 Patients

Efrain Olszewer, MD and James P. Carter, MD, DrPH

Dr. Olszewer is a cardiologist in Sao Paulo, Brazil, where this study was conducted.
Dr. Carter is Professor and Head, Nutrition Section, Tulane University School of Public Health and Tropical Medicine, New Orleans, Louisiana.

ABSTRACT: Results are presented of a 28-month retrospective analysis of 2,870 patients with documented atherosclerosis and other degenerative, age associated diseases who were treated with intravenous disodium magnesium EDTA chelation therapy. Observed benefits strongly support the use of EDTA chelation therapy for those conditions. Marked improvement occurred in 76.9% and good improvement occurred in 17% of treated patients with ischemic heart disease. Marked improvement occurred in 91% and good improvement occurred in 8% of treated patients with peripheral vascular disease and intermittent claudication. In patients with cerebrovascular and other degenerative cerebral diseases, 24% had marked improvement, and 30% had good improvement. Of four patients with scleroderma, three had marked improvement and one had good improvement. Seventy-five percent of all patients had marked improvement in symptoms of vascular origin. Independent of pathology, 89% of all treated patients had marked or good improvement.

Journal of Advancement in Medicine, Volume 2, Numbers 1/2, Spring/Summer 1989
For the full-text study, go to your nearest medical library or order
The Textbook of EDTA Chelation Therapy.

BACK TO CHELATION RESEARCH

BACK TO MAIN CHELATION PAGE

Mount Rainier Clinic
503 First Street South, Suite 1
Yelm, Washington 98597, USA

Telephone: (360) 458-1061
FAX: (360) 458-1661

email: Click here to send us an email message

Last modified: Disclaimer